fluoxetine has been researched along with Electrocardiogram QT Prolonged in 18 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Forty patients with major depressive disorder (according to DSM-III-R criteria) were enrolled in a 6-week double-blind parallel group study of fluoxetine (N = 20) or doxepin (N = 20)." | 9.08 | Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. ( Baker, B; Dorian, P; Irvine, MJ; Mitchell, J; Sandor, P; Schell, C; Shapiro, C, 1997) |
| "Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 5.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
| " Forty patients with major depressive disorder (according to DSM-III-R criteria) were enrolled in a 6-week double-blind parallel group study of fluoxetine (N = 20) or doxepin (N = 20)." | 5.08 | Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. ( Baker, B; Dorian, P; Irvine, MJ; Mitchell, J; Sandor, P; Schell, C; Shapiro, C, 1997) |
| "Drug-induced long QT syndrome is generally ascribed to inhibition of the cardiac rapid delayed rectifier potassium current (IKr)." | 1.39 | Slow delayed rectifier potassium current blockade contributes importantly to drug-induced long QT syndrome. ( Blom, MT; Klemens, CA; Langendijk, PN; Tan, HL; van Ginneken, AC; Veerman, CC; Verkerk, AO; Wilders, R, 2013) |
| "Fluoxetine (Prozac) was more potent at blocking hERG 1a/1b than 1a channels, yielding a corresponding reduction in the safety margin." | 1.37 | hERG subunit composition determines differential drug sensitivity. ( Abi-Gerges, N; Holkham, H; Jones, EM; Pollard, CE; Robertson, GA; Valentin, JP, 2011) |
| "Fluoxetine is a potent inhibitor of CYP2D6, and imipramine is metabolized by CYP2D6." | 1.33 | QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. ( Blackmon, CL; Nykamp, DL; Roberson, AG; Schmidt, PE, 2005) |
| "Fluoxetine is an antidepressant drug, only recently discovered to be a QT interval prolonging agent." | 1.33 | Prolonged QT interval in an infant of a fluoxetine treated mother. ( Dubnov, G; Fogelman, R; Merlob, P, 2005) |
| "Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 1.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| He, S | 1 |
| Moutaoufik, MT | 1 |
| Islam, S | 1 |
| Persad, A | 1 |
| Wu, A | 1 |
| Aly, KA | 1 |
| Fonge, H | 1 |
| Babu, M | 1 |
| Cayabyab, FS | 1 |
| Wei, A | 1 |
| Peng, J | 1 |
| Gu, Z | 1 |
| Li, J | 1 |
| Rizzo, R | 1 |
| Gulisano, M | 1 |
| Calì, PV | 1 |
| Di Pino, A | 1 |
| Peters, S | 1 |
| Veerman, CC | 1 |
| Verkerk, AO | 1 |
| Blom, MT | 1 |
| Klemens, CA | 2 |
| Langendijk, PN | 1 |
| van Ginneken, AC | 1 |
| Wilders, R | 1 |
| Tan, HL | 1 |
| Yeung, KS | 1 |
| Meanwell, NA | 1 |
| Abi-Gerges, N | 1 |
| Holkham, H | 1 |
| Jones, EM | 1 |
| Pollard, CE | 1 |
| Valentin, JP | 1 |
| Robertson, GA | 1 |
| Jaffe, R | 1 |
| Leavitt, R | 1 |
| Wind, T | 1 |
| Nykamp, DL | 1 |
| Blackmon, CL | 1 |
| Schmidt, PE | 1 |
| Roberson, AG | 1 |
| Dubnov, G | 1 |
| Fogelman, R | 1 |
| Merlob, P | 1 |
| Wilting, I | 1 |
| Smals, OM | 1 |
| Holwerda, NJ | 1 |
| Meyboom, RH | 1 |
| de Bruin, ML | 1 |
| Egberts, TC | 1 |
| Adetunji, B | 1 |
| Basil, B | 1 |
| Mathews, M | 1 |
| Osinowo, T | 1 |
| Hancox, JC | 2 |
| Mitcheson, JS | 1 |
| Rajamani, S | 1 |
| Eckhardt, LL | 1 |
| Valdivia, CR | 1 |
| Gillman, BM | 1 |
| Anderson, CL | 1 |
| Holzem, KM | 1 |
| Delisle, BP | 1 |
| Anson, BD | 1 |
| Makielski, JC | 1 |
| January, CT | 1 |
| Baker, B | 1 |
| Dorian, P | 1 |
| Sandor, P | 1 |
| Shapiro, C | 1 |
| Schell, C | 1 |
| Mitchell, J | 1 |
| Irvine, MJ | 1 |
| Lherm, T | 1 |
| Lottin, F | 1 |
| Larbi, D | 1 |
| Bray, M | 1 |
| Legall, C | 1 |
| Caen, D | 1 |
| Varriale, P | 1 |
| Witchel, HJ | 1 |
| Pabbathi, VK | 1 |
| Hofmann, G | 1 |
| Paul, AA | 1 |
2 reviews available for fluoxetine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Carcinogenesis; Cell Movement; Cell Proliferation; | 2020 |
QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Defibrillators, Implantable; Drug Inter | 2017 |
1 trial available for fluoxetine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disord | 1997 |
15 other studies available for fluoxetine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Mandatory electrocardiographic monitoring in young patients treated with psychoactive drugs.
Topics: Antipsychotic Agents; Child; Electrocardiography; Fluoxetine; Humans; Long QT Syndrome; Male; Pimozi | 2013 |
QRS fragmentation in acquired long QT syndrome does not always predict torsades of pointes tachycardia: a case report.
Topics: Antidepressive Agents, Second-Generation; Diagnosis, Differential; Electrocardiography; Female; Fluo | 2014 |
Slow delayed rectifier potassium current blockade contributes importantly to drug-induced long QT syndrome.
Topics: Action Potentials; Cells, Cultured; Computer Simulation; Echocardiography; Electrocardiography; Exer | 2013 |
Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Humans; Inhibitory Concentrati | 2008 |
hERG subunit composition determines differential drug sensitivity.
Topics: Action Potentials; Arrhythmias, Cardiac; Cell Line, Transformed; Drug Evaluation, Preclinical; Ether | 2011 |
QTc prolongation in multiple drug overdose.
Topics: Adult; Bupropion; Drug Overdose; Fluoxetine; Humans; Long QT Syndrome; Male; Piperazines; Psychotic | 2004 |
QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.
Topics: Anti-Infective Agents, Urinary; Antidepressive Agents; Cytochrome P-450 CYP2D6 Inhibitors; Drug Syne | 2005 |
Prolonged QT interval in an infant of a fluoxetine treated mother.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Electrocardiography; Female; Fluoxeti | 2005 |
QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine.
Topics: Aged, 80 and over; Female; Fluoxetine; Humans; Long QT Syndrome; Selective Serotonin Reuptake Inhibi | 2006 |
Should the Physician's Desk Reference contraindicate the use of chlorpromazine-fluoxetine combination? A case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chlorpromazine; Contraindicat | 2006 |
Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.
Topics: Antidepressive Agents, Second-Generation; Drug Overdose; Ether-A-Go-Go Potassium Channels; Female; F | 2006 |
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Blotting, Western; Cell Line; Cell Membrane; Cisapr | 2006 |
[Torsade de pointes after poisoning with fluoxetine alone].
Topics: Adult; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Electrocardiograp | 2000 |
Fluoxetine (Prozac) as a cause of QT prolongation.
Topics: Depression; Electrophysiology; Fluoxetine; Humans; Long QT Syndrome; Male; Middle Aged; Selective Se | 2001 |
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.
Topics: Animals; Calcium Channels, L-Type; Cation Transport Proteins; Citalopram; Ether-A-Go-Go Potassium Ch | 2002 |